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Cysteinyl leukotrienes (LTs [cys-LTs]) are lipid 
inflammatory mediators generated in vivo by 
mast cells (MCs), eosinophils, myeloid DCs, ba-
sophils, and macrophages (Kanaoka and Boyce, 
2004). They abound in mucosal inflammation, 
play a validated role in human asthma (Wenzel   
et al., 1990; Israel et al., 1996; Liu et al., 1996), 
and are important mediators in mouse mod-
els of pulmonary inflammation, remodeling, 
and  fibrosis  (Beller  et  al.,  2004;  Henderson   
et al., 2006; Kim et al., 2006). LTC4, the par-
ent  cys-LT,  is  synthesized  from  arachidonic 
acid, which is liberated by calcium-depen-
dent cPLA2 (cytosolic phospholipase A2) from 
membrane phospholipids (Clark et al., 1991). 
Arachidonic acid is then converted to LTA4 by 
5-lipoxygenase (5-LO) in concert with 5-LO– 
activating protein (Dixon et al., 1990; Malaviya 
et al., 1993). LTA4 is conjugated to reduced 
glutathione by LTC4 synthase, a homotrimeric 
integral nuclear membrane protein (Ago et al., 
2007),  forming  LTC4.  LTC4  is  exported  to 
the extracellular space by a multidrug-resistant 
protein after synthesis (Robbiani et al., 2000), 
where it is converted to LTD4 by -glutamyl 
leukotrienase-mediated  removal  of  glutamic 
acid (Shi et al., 2001). LTD4 is then converted 
to LTE4 by dipeptidase-mediated removal of 
glycine (Lee et al., 1983). Thus, the cys-LTs 
comprise three ligands that form in a spatially   
and  temporally  distinct  fashion.  LTC4  is  the 
only intracellular cys-LT, and LTD4 is the most 
powerful contractile agonist of the airway smooth 
muscle. The half-life of LTD4 is short (minutes) 
because of its rapid conversion to LTE4, effec-
tively limiting its duration of action in vivo. 
LTE4 is stable and excreted in the urine (Sala 
et al., 1990). The stability of LTE4 accounts for 
the fact that it is the dominant cys-LT detected 
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Of the potent lipid inflammatory mediators comprising the cysteinyl leukotrienes (LTs; LTC4, 
LTD4, and LTE4), only LTE4 is stable and abundant in vivo. Although LTE4 shows negligible 
activity at the type 1 and 2 receptors for cys-LTs (CysLT1R and CysLT2R), it is a powerful 
inducer of mucosal eosinophilia and airway hyperresponsiveness in humans with asthma. 
We show that the adenosine diphosphate (ADP)–reactive purinergic (P2Y12) receptor is 
required for LTE4-mediated pulmonary inflammation. P2Y12 receptor expression permits 
LTE4 -induced activation of extracellular signal-regulated kinase in Chinese hamster ovary 
cells and permits chemokine and prostaglandin D2 production by LAD2 cells, a human mast 
cell line. P2Y12 receptor expression by LAD2 cells is required for competition between 
radiolabeled ADP and unlabeled LTE4 but not for direct binding of LTE4, suggesting that 
P2Y12 complexes with another receptor to recognize LTE4. Administration of LTE4 to the 
airways of sensitized mice potentiates eosinophilia, goblet cell metaplasia, and expression 
of interleukin-13 in response to low-dose aerosolized allergen. These responses persist in 
mice lacking both CysLT1R and CysLT2R but not in mice lacking P2Y12 receptors. The effects 
of LTE4 on P2Y12 in the airway were abrogated by platelet depletion. Thus, the P2Y12 recep-
tor is required for proinflammatory actions of the stable abundant mediator LTE4 and is a 
novel potential therapeutic target for asthma.
© 2009 Paruchuri et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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generation in vivo (Israel et al., 1996; Liu et al., 1996). Iden-
tification of receptors and pathways through which LTE4 
exerts its effects may be highly significant in terms of the 
pathobiology of mucosal inflammation, as well as the treat-
ment of asthma, AERD, and related diseases in which local 
concentrations of LTE4 are elevated and/or end-organ reac-
tivity to LTE4 is high.
MCs respond strongly to cys-LTs and are a useful cell 
type for modeling cys-LT–induced signaling events and re-
ceptor functions. We previously demonstrated that human 
and mouse MCs express both CysLT1R (Mellor et al., 2001) 
and CysLT2R (Mellor et al. 2003) and that these receptors 
constitutively form heterodimers on this cell type (Jiang et al., 
2007). Stimulation of MCs with LTD4, the most potent 
agonist of the CysLT1R, transactivates the kit tyrosine ki-
nase (Jiang et al., 2006), induces calcium flux (Mellor et al., 
2001), and phosphorylates extracellular signal-regulated ki-
nase (ERK; Jiang et al., 2006). These signaling events amplify 
MC proliferation and induce their generation of cytokines 
and chemokines (Mellor et al., 2002). CysLT1R is required 
for all of these LTD4-induced responses, whereas CysLT2R 
inhibits them (Jiang et al., 2007). MCs also express several 
P2Y receptors (Feng et al., 2004). We recently reported that 
LTE4 induces ERK activation and COX-2 expression, and 
causes prostaglandin (PG) D2 and macrophage inflammatory 
protein 1 (MIP-1) generation by LAD2 cells, a well-
differentiated human MC line (Kirshenbaum et al. 2003;   
Paruchuri et al., 2008), and to a lesser extent by primary cord 
blood-derived human MCs (hMCs). LTE4-mediated produc-
tion of PGD2 by LAD2 cells was unaffected by short hairpin 
RNA (shRNA)–mediated knockdown of either CysLT1R 
or CysLT2R (Paruchuri et al., 2008), supporting the pres-
ence of a previously unrecognized LTE4-reactive receptor on 
this cell type. A computer model (Nonaka et al., 2005) had 
predicted that the P2Y12 receptor, an adenosine diphosphate 
(ADP)–reactive GPCR which is the target of the thieno-
pyridine anti-thrombotic drugs (Foster et al., 2001), could 
be an LTE4 receptor. In this study, we demonstrate a po-
tent unique proinflammatory function for LTE4 in the lung, 
and we demonstrate that P2Y12 receptors are required for 
the functions of LTE4 in vitro and in the lung in vivo. Our 
results suggest that P2Y12 receptors may be a novel target for 
the treatment of asthma.
RESULTS
Recombinant human P2Y12 receptors convey cellular 
responses to LTE4
To determine if P2Y12 receptors could mediate responses to 
LTE4, we stably transfected Chinese hamster ovary (CHO) 
cells  (which  do  not  natively  express  classical  CysLTRs 
[Maekawa et al., 2001] or P2Y12 receptors) with constructs 
encoding the human P2Y12 receptor protein in forward and 
reverse orientation. The transfectants were stimulated with 
exogenous LTC4, LTD4, or LTE4. Fura-2 AM–loaded CHO 
cells expressing P2Y12 receptors failed to flux calcium in re-
sponse to LTE4 but did exhibit a response to ADP, reflecting 
in biological fluids. Consequently, LTE4 levels can be moni-
tored in the urine (Drazen et al., 1992), sputum (Lam et al., 
1988), and exhaled breath condensate (Csoma et al., 2002) as 
an index of the cys-LT synthetic pathway activity in human 
disease states such as asthma, where its concentrations can be 
markedly elevated.
To date, two G protein–coupled receptors (GPCRs) for 
cys-LTs, termed type 1 and type 2 cys-LT receptors (CysLT1R 
and CysLT2R), have been cloned and characterized (Lynch 
et al., 1999; Heise et al., 2000). These receptors share 38% 
amino acid identity. Each is 24–32% identical to the puriner-
gic (P2Y) class of GPCRs that regulate cellular responses to 
extracellular nucleotides (Mellor et al., 2001), suggesting a 
phylogenetic relationship between these two GPCR classes. 
The human CysLT1R, encoded by a gene on chromosome 
Xq21.13, is a high-affinity receptor for LTD4 (Kd 1 nM; 
Lynch et al., 1999), whereas the human CysLT2R is encoded 
by a gene on chromosome 13q14 and has equal affinity for 
LTC4 and LTD4 (Kd 10 nM; Heise et al., 2000). As neither 
receptor has significant affinity for LTE4, the existence of an 
additional cys-LT receptor with a preference for LTE4 has 
long been suspected. Early studies demonstrated that purified 
LTE4 is more potent than LTC4 or LTD4 for inducing con-
traction of guinea pig tracheal rings (Lee et al., 1984), whereas 
LTC4 and LTD4 were more potent on peripheral lung. Of 
the three cys-LTs, only LTE4 potentiates the contractile re-
sponse of guinea pig trachea to histamine, a response which 
can  be  blocked  by  the  administration  of  indomethacin,  a 
nonselective inhibitor of the cyclooxygenase (COX) enzymes 
(Lee et al., 1984). LTE4 inhalation by asthmatic individuals 
potentiates airway hyperresponsiveness to subsequent chal-
lenges with histamine. This potentiation is also blocked by 
oral administration of indomethacin (Christie et al., 1992a). 
Inhalation of LTE4, but not of LTD4, causes eosinophils, ba-
sophils, and MCs to accumulate in the bronchial mucosa of 
asthmatic individuals (Laitinen et al., 1993; Gauvreau et al., 
2001). Patients with aspirin-exacerbated respiratory disease 
(AERD), a syndrome characterized by asthma, nasal poly-
posis, and marked cys-LT overproduction, exhibit selectively 
enhanced bronchoconstriction in response to LTE4 relative 
to LTC4 or to histamine when compared with aspirin-toler-
ant asthmatic individuals (Christie et al., 1993). Mice lacking 
both CysLT1R and CysLT2R (Cysltr1/Cysltr2/ mice) ex-
hibit enhanced skin swelling in response to intracutaneous 
LTE4 relative to WT controls, indicating that a putative 
LTE4-reactive GPCR (termed CysLTER) exists in the skin 
(Maekawa et al. 2008). Thus, the potency of LTE4 as an in-
ducer of inflammatory and physiological effects in vivo is not 
explained by the pharmacology of the classical GPCRs for 
cys-LTs, which preferentially bind the metabolic precursors 
of LTE4. Thus, the three cys-LTs are all potent mediators, 
and show considerable tissue specificity for their respective 
actions. Both a 5-LO inhibitor (zileuton) and the drugs that 
block CysLT1R (Knorr et al., 1998) show clinical efficacy in 
asthma, despite the negligible activity of LTE4 at CysLT1R 
and the fact that zileuton blocks only 50% of cys-LT JEM VOL. 206, October 26, 2009 
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failed to attenuate LTD4- or LTE4-mediated calcium flux in 
LAD2 cells (Fig. 2 A). We determined the effect of MK571 
and 2-MesAMP on MIP-1 generation by LAD2 cells in re-
sponse to stimulation for 6 h with LTD4 and LTE4, using IgE 
plus anti-IgE as a positive control. LTE4 at doses of 100 and 
500 nM induced the generation of large amounts of MIP-1, 
exceeding the amounts generated in response to LTD4 and to 
IgE plus anti-IgE (Fig. 2 B). Pretreatment of the LAD2 cells 
with 2-MesAMP blocked the LTE4-mediated increment in 
MIP-1 production by >50% (Fig. 2 B). 2-MesAMP also 
reduced the response to the higher concentrations of LTD4. 
MK571 suppressed the response to both ligands and was ad-
ditive with 2-MesAMP for the suppression of the response to 
LTD4. Neither antagonist altered the production of MIP-1 
in response to IgE plus anti-IgE. To exclude potential off-
target effects of the inhibitors, samples of LAD2 cells were 
transfected with lentiviruses encoding a P2Y12 sequence- 
specific shRNA, a CysLT1R-specific shRNA, or an empty 
vector control before stimulation. Knockdown of P2Y12 re-
ceptors decreased the receptor messenger RNA (mRNA) 
expression by 90% (Fig. 2 D) and did not alter expression 
of CysLT1R or CysLT2R proteins (not depicted). P2Y12 re-
ceptor knockdown nearly abrogated MIP-1 production, com-
pletely eliminated PGD2 production in response to LTE4, and 
minimally affected the response to LTD4. The knockdown of 
CysLT1R completely blocked MIP-1 and PGD2 produc-
tion in response to LTD4 and slightly (but not significantly) 
decreased the responses to LTE4 (Fig. 2 C, bottom). Neither 
knockdown altered MIP-1 generation or PGD2 production 
in response to IgE–anti-IgE (Fig. 2 C). LTE4-mediated 
endogenous P2Y1 receptors (Fig. 1 A). However, CHO cells 
transfected with the P2Y12 receptor construct in forward (but 
not reverse) orientation responded to LTE4 (and to LTD4) 
with ERK activation (Fig. 1 B), which occurred at doses as 
low as 1 nM and reached a plateau at 100 nM (Fig. S1). The 
cys-LT–induced  ERK  activation  was  partially  blocked  by 
pretreatment of the cells with 2-methylthioadenosine mono-
phosphate (2-MesAMP), a selective antagonist of the P2Y12 
receptor (Fig. 1 C), and was also sensitive to pertussis toxin 
(PTX; Fig. 1 D) but was resistant to MK571 (Fig. 1 D), an 
inhibitor which blocks CysLT1R and some P2Y receptors 
(Mamedova et al., 2005). Although ERK activation in the 
P2Y12 receptor transfectants was at least as robust in response 
to LTE4 as to LTD4 (Fig. 1 D), CysLT1R and CysLT2R 
transfectants reacted to LTD4 in marked preference to LTE4, 
even at high (500 nM) ligand concentrations. These responses 
were resistant to PTX and 2-MesAMP and, in the case of the 
CysLT1R transfectants, susceptible to MK571.
P2Y12 receptor requirement for LTE4-mediated activation 
and binding to LAD2 cells
We had previously reported that LAD2 cells (a well-differen-
tiated human MC sarcoma line; Kirshenbaum et al., 2003) 
exhibited activation responses to LTE4 > LTD4. To deter-
mine whether P2Y12 receptors were responsible for these re-
sponses, Fura-2 AM–loaded LAD2 cells were stimulated with 
LTD4 or LTE4 in the presence or absence of 2-MesAMP or 
MK571.  As  reported  previously  (Paruchuri  et  al.,  2008), 
MK571 blocked calcium responses of LAD2 cells to both 
ligands (unpublished data). In contrast, 2-MesAMP treatment 
Figure 1.  Activation by recombinant human P2Y12 receptors in response to cys-LTs. The human P2Y12 receptor complementary DNA (cDNA) was 
cloned in forward and reverse orientation into the expression vector pEF1/His B and transfected into CHO cells using Fugene HD reagent. Stably express-
ing clones were selected using 1,000 µg/ml G418, and expression of the construct was confirmed by cytofluorographic detection of the polyhistidine (HIS) 
tag. (A) Calcium fluxes in CHO transfectants in response to 500 nM LTE4, 500 nM LTD4, and 100 µM ADP. Results in a second experiment were identical.  
(B) SDS-PAGE immunoblots showing phosphorylation of ERK2 by CHO cells stably expressing human P2Y12 receptors in reverse (negative control) or for-
ward orientations. Cells were stimulated with 100 µM ADP (positive control ligand), 500 nM LTD4, or 500 nM LTE4 for 15 min. The blots were stripped and 
reprobed with an antibody recognizing total ERK1 and ERK2. Dose responses are displayed in Fig. S1. (C) Effect of the selective P2Y12 receptor antagonist 
2-MesAMP (MeS) on ligand-induced ERK phosphorylation. P2Y12 receptor-expressing CHO cells were stimulated with the same doses of agonists used in 
A, in the absence or presence of 100 µM 2-MesAMP. (D) Comparison of P2Y12 receptor-mediated responses to cys-LTs with those of recombinant human 
CysLT1R and CysLT2R expressed in CHO cells, and the effect of 1 µM of the CysLT1R antagonist MK571. Data in B–D are from individual experiments that 
were repeated at least three times with similar results.2546 LEUKOTRIENE E4 AND P2Y12 RECEPTORS | Paruchuri et al.
from the transfectants expressing the forward construct bound 
[33P]2-MesADP, a selective P2Y12 receptor agonist. In con-
trast to ADP binding to LAD2 membranes, this binding was 
not competed by unlabeled LTE4 or LTD4 (Fig. S3 D). Ad-
ditionally, these membranes failed to bind [3H]LTE4 (unpub-
lished data).
LTE4 potentiates allergen-induced bronchial inflammation
To determine whether LTE4 could induce or potentiate histo-
logical signatures of pulmonary inflammation in mice, we de-
termined the effect of 2.2 nmol of intranasal LTE4 administered 
on three successive days on the lung histology of naive BALB/c 
mice. We compared the effect to that of LTD4. The lungs of 
naive BALB/c mice showed no evidence of cellular influx or 
goblet cell metaplasia after three doses of either cys-LT alone 
(unpublished data). Thus, we sought to determine whether ei-
ther cys-LT amplified pulmonary inflammation induced by 
the inhalation of low-dose allergen in sensitized mice. 2 wk   
after sensitization with chicken egg OVA by i.p. injection, 
BALB/c mice received inhalation challenges on three consec-
utive days with low-dose OVA (0.1%) for 30 min. 30 min be-
fore each challenge, the mice received 2.2 nmol of intranasal 
LTD4, LTE4, or a buffer control. A cohort of mice treated 
MIP-1 generation (Fig. S2 A) and ERK activation (Fig. S2 B) 
were not altered by treatment of LAD2 cells with apyrase to 
degrade extracellular ADP.
To determine whether P2Y12 receptors directly mediated 
LTE4 binding, membranes were prepared from LAD2 cells 
with and without P2Y12 knockdown. We first performed 
competitive radioligand binding assays using [3H]ADP (the 
known natural ligand of P2Y12 receptors) and unlabeled LTs 
as competitors. Unlabeled LTE4 competed with labeled ADP, 
blocking 39 ± 9 and 50 ± 9% of specific ADP binding at doses 
of 0.1 and 1 nM, respectively, and reaching a plateau (60 ± 
7%) at 1 µM (mean ± SEM for four separate experiments, as 
shown for one experiment [Fig. S3 A]). LTE4 was more effi-
cacious than LTD4 (Fig. S3 B). Knockdown of P2Y12 recep-
tors reduced binding of [3H]ADP by 40–60% and completely 
eliminated competition by LTE4 (Fig. S3, A and B, right). 
LAD2 cell membranes weakly bound [3H]LTE4 (converted 
from commercially prepared [3H]LTD4; Fig. S3 C), but spe-
cific binding of [3H]LTE4 was not altered by the knockdown 
of P2Y12 receptor (Fig. S3 C). To determine whether LTE4 
could block the ADP binding of P2Y12 receptors expressed in 
isolation, the human forward and reverse P2Y12 constructs 
were transiently expressed in COS-7 cells. The membranes 
Figure 2.  Requirement for P2Y12 receptors in LTE4-mediated MC activation. (A) Calcium flux of LAD2 cells stimulated with 500 nM of the LTs in 
the presence or absence of 100 µM 2-MesAMP. MK571 completely blocked both LTD4- and LTE4-mediated calcium fluxes (not depicted). Results in two 
additional experiments were similar. (B) Effect of 100 µM 2-MesAMP, 1 µM MK571, or both on MIP-1 generation by LAD2 cells in response to the indi-
cated doses of LTD4 and LTE4. Cells sensitized overnight with IgE and challenged with anti-IgE were used as the positive control. (C) Effect of shRNA-
mediated knockdowns of CysLT1R or P2Y12 receptors on MIP-1 generation (left) and PGD2 generation (right) by LAD2 cells stimulated with 100 nM LTD4 or 
100 nM LTE4. Results in B and C are mean ± SEM from three independent experiments each. Statistical differences were assessed by analysis of variance. 
(D) Effect of shRNA-mediated knockdown of P2Y12 receptor mRNA expression by LAD2 cells. Real-time PCR was performed on an ABI PRISM 7700 
Sequence detection system. FACS analysis was used to confirm the knockdowns of CysLT1R (not depicted). Mock, cells transfected with empty lentivirus. 
Results in two additional experiments were similar.JEM VOL. 206, October 26, 2009 
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that covalently binds to and irreversibly inactivates P2Y12 
receptors (Savi et al., 2006). Drug treatment began 2 d before 
the first administration of LTs to allow conversion of the 
prodrug. A separate cohort of sensitized mice was maintained 
without clopidogrel treatment as a control group. Both groups 
were challenged with low-dose OVA with or without addi-
tional LTE4. Treatment with clopidogrel eliminated LTE4-
induced potentiation of both inflammation and goblet cell 
metaplasia (Fig. 4, A and B). To determine the effect of P2Y12 
receptor blockade on the induced expression of mRNAs 
encoding proteins involved in goblet cell metaplasia, real-
time PCR was used to analyze the lungs of the mice for the 
expression of IL-13 and the goblet cell–associated glycopro-
tein MUC5AC. LTE4 modestly increased the expression of 
both transcripts, whereas clopidogrel treatment substantially 
suppressed the expression of both (Fig. 4 C). There was no 
detectable induction of IL-4 or IL-5 transcripts (unpub-
lished data).
Because pharmacologic antagonists can act in an off-
target manner, we sought to determine the receptors required 
to mediate the effect of LTE4 in the lungs of allergen-sensi-
tized and -challenged mice using a molecular approach. First, 
we studied the ability of LTE4 to amplify pulmonary inflam-
mation in OVA-sensitized and -challenged C57BL/6 mice 
lacking P2Y12 receptors (p2ry12/ mice; Andre et al., 2003) 
with 1% OVA were maintained as a positive control. The mice 
were then euthanized, their bronchoalveolar lavage (BAL) 
fluid was collected, and their lungs were examined histologi-
cally for evidence of inflammation and goblet cell metaplasia. 
Compared with saline-treated sensitized mice, mice challenged 
with low-dose OVA demonstrated low-grade BAL fluid eo-
sinophilia (Fig. 3 A). These mice showed very mild pulmonary 
inflammation, as indicated by the accumulation of lympho-
cytes, plasma cells, and eosinophils around the bronchovascular 
bundles (Fig. 3, B and C). The administration of LTD4 did not 
increase BAL fluid eosinophilia (Fig. 3 A) and slightly potenti-
ated both bronchovascular inflammation (Fig. 3, B and C) and 
goblet cell metaplasia (Fig. 3, D and E). In contrast, LTE4 sig-
nificantly enhanced BAL fluid eosinophilia (Fig. 3 A), inflam-
mation (Fig. 3, B and C), and goblet cell metaplasia (Fig. 3, 
D and E). The extent of the cellularity and goblet cell re-
sponses of the LTE4-treated animals approached the levels of 
these parameters in the mice treated with 1% OVA.
LTE4-mediated pulmonary inflammation depends on P2Y12 
receptors and is independent of classical CysLTRs
To determine whether P2Y12 receptors accounted for the 
LTE4-mediated augmentation of pulmonary inflammation, 
sensitized mice were treated with clopidogrel, an antithrom-
botic agent that is converted in vivo to an active metabolite 
Figure 3.  LTE4-mediated amplification of allergen-induced pulmonary inflammation. Male BALB/c mice (6–8 wk old) were sensitized on days 0 and 7 
with i.p. injections of 10 µg Alum-precipitated chicken egg OVA. Mice were challenged with LTs on days 13–15 and OVA on days 14–16 as described in the 
text. Mice were euthanized 24 h after their third and final aerosol challenge. (A) BAL fluid total cell counts (top) with percentages (middle) and total num-
bers per mouse (bottom) of eosinophils. (B) Quantitative analysis of pulmonary inflammation performed on 0.5-µm-thick glycol methacrylate sections of 
lungs. The extent of cellular infiltration in 15 bronchovascular bundles of each mouse in hematoxylin and eosin (H&E)–stained sections was evaluated with-
out knowledge of the treatment groups. (C) Representative fields of H&E-stained lungs from mice from the indicated experimental groups. (D) Morphomet-
ric analysis of goblet cell metaplasia, measured as the numbers of periodic acid–Schiff (PAS)-positive goblet cells per millimeter of bronchial basal lamina 
(determined by ImageJ image analysis software). (E) Representative PAS stains showing goblet cells (arrows). Results in A, B, and D are mean ± SEM from 
eight to nine mice per group. The experiments were repeated three times. Statistical differences were determined by analysis of variance. Bars, 100 µm.2548 LEUKOTRIENE E4 AND P2Y12 RECEPTORS | Paruchuri et al.
Figure 4.  Role of P2Y12 receptors on potentiation of pulmonary inflammation by LTE4. (A) Bronchovascular inflammation (top) and goblet cell 
metaplasia in sensitized mice challenged with low-dose OVA with or without the prior administration of 2.2 nmol LTD4 or LTE4 30 min before each chal-
lenge. 500 µg/ml clopidogrel was added to the drinking water of the indicated groups of mice for 72 h before the first intranasal dose of LTs and was 
maintained throughout the treatment. Results are mean ± SEM from at least nine mice in each group. The experiments were repeated three times with 
similar results. (B) PAS stains (left) from representative mice in the indicated groups showing the effect of clopidogrel on goblet cell metaplasia. Higher 
magnification images of H&E stains (right) from the same animals showing cellular characteristics of the bronchovascular infiltrates. (C) Effect of clopi-
dogrel administration on the steady-state expression of IL-13 and MUC5AC mRNA as determined by real-time PCR of whole lung RNA extracted 24 h 
after the last OVA challenge of the indicated groups. Data are mean ± SEM from four to five mice per group from a single experiment. Results in a second 
experiment were similar. (D–F) Male and female C57BL/6 p2ry12/ mice and age- and sex-matched controls were sensitized and challenged with 0.1% 
aerosolized OVA on three consecutive days with or without intranasal LTE4 30 min before each challenge. (D) Total cell numbers (top), percentages of  
eosinophils (middle), and total numbers of eosinophils (bottom) in BAL fluid recovered 24 h after the last challenge with OVA. (E) Goblet cell metaplasia 
(top) and representative PAS stains (bottom) from WT and p2ry12/ mice subjected to the same protocol. (F) Inflammation scores from the same mice. Data in  
D–F are from four mice per group. Results in a second experiment were similar. (G) BALB/c Cysltr1/Cysltr2/ mice and age-matched WT controls were 
subjected to the same protocol as the p2ry12/ mice. Total cell numbers (top), percentages of eosinophils (middle), and total numbers of eosinophils 
(bottom) in BAL fluid recovered 24 h after the last challenge with OVA. Results are from six mice per group. Three experiments were performed with simi-
lar results. (H) Goblet cell numbers (top) and representative PAS stains (bottom). (I) Quantitative assessment of bronchovascular inflammation as deter-
mined by H&E stain (top). Results are from six mice per group. Representative stains are shown (bottom). Error bars represent ± SEM. Bars, 100 µm.JEM VOL. 206, October 26, 2009 
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with or without clopidogrel treatment. Two different doses 
of Der f were used to elicit moderate (3 µg) and severe (10 µg) 
inflammation, respectively. At both antigen doses, the mice 
treated with clopidogrel showed 75% attenuation of BAL 
fluid eosinophilia (unpublished data), as well as significant 
reductions in pulmonary inflammation, and goblet cell meta-
plasia compared with the cohort that did not receive clopido-
grel (Fig. 5, A and B).
LTE4/P2Y12 receptor-mediated amplification of pulmonary 
inflammation requires platelets
Because P2Y12 receptors are essential for normal platelet acti-
vation in vivo (Andre et al., 2003), we sought to determine 
whether platelets were required for the response of sensitized 
challenged mice to exogenous LTE4. Platelets were depleted 
in sensitized BALB/c mice by the i.v. injection of a rat mAb 
against mouse CD42b (GPIb; Nieswandt et al., 2000) or an 
isotype-matched control IgG 48 h before to the first admin-
istration of LTD4 or LTE4. Treatment with the anti-CD42b 
antibody depleted platelets almost completely (99% depletion 
[unpublished data]) at the time of the first dose of LT. Platelet 
depletion resulted in a complete loss of the LTE4-mediated 
potentiation of airway eosinophilia, inflammation, and goblet 
cell metaplasia (Fig. 6, A and B). The effect of platelet deple-
tion was identical to the effect of treatment of the mice with 
clopidogrel, and the two treatments were not additive (Fig. 6 B). 
Platelet depletion, like clopidogrel treatment, sharply reduced 
the LTE4-mediated expression of mRNA encoding IL-13 
along  with  age-  and  sex-matched  C57BL/6  controls.  Al-
though cellular infiltration into the lung and BAL fluid was 
less pronounced in the C57BL/6 mice than in the BALB/c 
mice, LTE4 potentiated BAL fluid eosinophilia (Fig. 4 D), 
goblet cell metaplasia (Fig. 4 E), and bronchovascular infiltra-
tion (Fig. 4 F) in the WT controls, all of which were severely 
blunted in the p2ry12/ mice (Fig. 4, D–F). To determine 
whether classical GPCRs for cys-LTs were also required for 
the LTE4 effects, BALB/c mice lacking both CysLT1R and 
CysLT2R (Cysltr1/Cysltr2/ mice; Maekawa et al., 2008) 
were also studied. Because of limited numbers of available 
mice, all animals were sensitized and challenged with low-
dose OVA, and half were treated with exogenous LTE4. 
Strikingly, the potentiation of OVA-induced BAL fluid eo-
sinophilia (Fig. 4 G), goblet cell metaplasia (Fig. 4 H), and 
inflammation (Fig. 4 I) by LTE4 were completely intact in 
the Cysltr1/Cysltr2/ mice, indicating that LTE4 was work-
ing independently of the known GPCRs for cys-LTs. Thus, 
the intrapulmonary actions of LTE4 in vivo require P2Y12 
receptors but not classical cys-LT–reactive GPCRs.
Blockade of P2Y12 receptors blunts pulmonary inflammation 
induced by house dust mite antigen
To determine whether pharmacologic blockade of P2Y12 re-
ceptors altered pulmonary inflammatory responses in a more 
physiological model of pulmonary inflammation, C57BL/6 
mice were administered an extract of house dust mite Derma-
tophagoides farinae (Der f) intranasally twice weekly for 3 wk, 
Figure 5.  Role of P2Y12 receptors in inflammation mediated by dust mite allergen. C57BL/6 mice were treated intranasally with the indicated 
dose of Der f extract twice weekly for 3 wk. Animals were euthanized 24 h after the last dose. (A) Effect of clopidogrel treatment on bronchovascular 
inflammation and goblet cell metaplasia in C57BL/6 mice subjected to intranasal challenge with the indicated doses of an extract from the house dust 
mite. Results are the mean ± SEM from five mice per group. The experiment was repeated thee times with similar results. (B) Representative PAS stains of 
the lungs from mice in the indicated groups. Bar, 100 µm.2550 LEUKOTRIENE E4 AND P2Y12 RECEPTORS | Paruchuri et al.
of asthma is established by the fact that 5-LO inhibitors (Israel 
et al., 1996; Liu et al., 1996) and CysLT1R antagonists (Knorr 
et al., 1998) have clinical efficacy. The cloning and functional 
characterization of the CysLT1R (Lynch et al., 1999) and 
CysLT2R (Heise et al., 2000) explained the pharmacology of 
LTC4 and LTD4 predicted from studies of contractile tissues 
(Lee et al., 1984). The finding that neither GPCR showed 
significant binding or reactivity to LTE4 was surprising given 
the plethora of data in human and animal studies that indicate 
the unique characteristics of this stable ligand relative to its 
short-lived precursors (Christie et al., 1992a, 1993; Laitinen   
et al., 1993; Gauvreau et al., 2001). Because we had previously 
demonstrated that LTE4 could activate LAD2 cells by a mech-
anism independent of CysLT1R and CysLT2R (Paruchuri   
et al., 2008), and because LTE4 was previously identified by 
an in silico model as a potential surrogate ligand for the P2Y12 
receptor (Nonaka et al., 2005), we undertook this study to 
determine whether the P2Y12 receptor was a bona fide LTE4-
reactive receptor and to determine its contribution to LTE4-
induced proinflammatory events.
We first established that recombinant human P2Y12 re-
ceptor protein conveyed activation responses by CHO cells 
to LTE4. Unlike most members of the P2Y receptor class, 
native P2Y12 receptors do not couple to Gq proteins or ac-
tivate calcium flux; instead, they induce signaling through 
PTX-sensitive  Gi2  proteins  when  stimulated  with  ADP 
(Foster et al. 2001; Lova et al., 2002; Woulfe et al., 2002). It 
was, thus, not surprising that CHO cells expressing P2Y12 re-
ceptors failed to flux calcium in response to cys-LTs (Fig. 1 A) 
or  that  blockade  of  P2Y12  receptors  on  LAD2  cells  with   
2-MesAMP failed to alter cys-LT–mediated calcium flux 
(Fig. 2 A), which was totally abrogated by MK571. How-
ever, heterologously expressed P2Y12 receptors responded to 
LTE4 with PTX-sensitive ERK activation (Fig. 1). The dose 
range for this response (Fig. S1) is similar to the LTE4 dose 
range required to compete with radiolabeled ADP for bind-
ing to LAD2 cell membranes (Fig. S3) and is consistent with 
that reported by Nonaka et al. (2005) using a P2Y12-G16 
fusion protein to demonstrate calcium flux, also in CHO cells. 
The finding that cys-LT–induced ERK activation in the 
transfectants was resistant to MK571 (Fig. 1 D) implies that 
P2Y12 receptors could contribute to an element of cys-LT–
driven pathobiology that is relatively selective for LTE4 and 
may resist conventional CysLT1R antagonists. This element 
may be especially relevant to pathological situations where 
LTE4 is abundant as a result of its relative stability.
In our previous study, LTE4 had exhibited unanticipated 
potency for inducing ERK activation and the generation 
of MIP-1 and COX-2–dependent PGD2 by LAD2 cells 
(Paruchuri et al., 2008). Because both ERK and calcium-
dependent transcriptional events are essential for MC activation, 
we sought to determine the potential contribution of P2Y12 
receptors to the activation responses of LAD2 cells to LTE4 
and to contrast these responses to those elicited by LTD4, the 
most potent CysLT1R ligand. Although ineffective for block-
ing cys-LT–induced calcium flux, 2-MesAMP effectively 
and MUC5AC (unpublished data). To determine whether 
LTE4 alone induced platelet activation (leading to ADP re-
lease with potential resultant autocrine stimulation of P2Y12 
receptors), human blood platelets were stimulated with 1 µM 
LTE4 or with 100 µM ADP, and degranulation was assessed 
by cytofluorographic detection of P-selectin (CD62P). As 
expected, ADP elicited CD62P expression, but no CD62P 
expression was detected in response to stimulation with 
LTE4 (Fig. 6 C).
DISCUSSION
This study establishes that P2Y12 receptors are essential for the 
actions of LTE4, the only long-lived stable abundant member 
of the cys-LTs, in inflamed lung. Our findings help to explain 
long-recognized but unexplained properties of LTE4 in air-
way biology. The involvement of cys-LTs in the pathobiology 
Figure 6.  Platelet dependence of the LTE4 effect on bronchial in-
flammation and goblet cell metaplasia. Sensitized mice were treated 
i.v. with 50 µg (2 µg/g body weight) of a monoclonal rat IgG directed 
against mouse CD42b (GPIb) or an equal amount of isotype control 
(both from Cemfret Analytics) 48 h before the first dose of LTE4. Each 
antibody was diluted in 50 µl of sterile saline. The depletion of platelets 
was confirmed by automated counting, and some mice were treated with 
clopidogrel. (A) PAS stains of the lungs of representative mice treated 
with isotype control (top) or with an anti-CD42 platelet-depleting anti-
body (bottom). (B) Inflammation (top) and goblet cell metaplasia (bottom) 
in the lungs of mice treated with the indicated LT and antibody. A cohort 
of mice was treated with clopidogrel as indicated. Results in B are from a 
single experiment with five mice per group. A second experiment with an 
equal number of mice showed similar results. Error bars represent ± SEM. 
(C) Cytofluorographic detection of surface expression of CD62P (P-selec-
tin) by platelets stimulated for 10 min with 100 µM ADP or 1 µM LTE4. 
Percentages of CD61-postitive platelets expressing CD62P are displayed in 
the top right quadrants. Results are from a single experiment performed 
three times on different donors. Bars, 100 µm.JEM VOL. 206, October 26, 2009 
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ating BAL fluid eosinophilia (Fig. 3 A), cellular infiltration of 
the bronchovascular bundles (Fig. 3, B and C), and goblet 
cell metaplasia (Fig. 3, D and E). Thus, LTE4 exceeds the 
efficacy of LTD4 for potentiating bronchial inflammation in 
both mouse and man, a pattern not explicable by the known 
properties of CysLT1R or CysLT2R. Several pieces of evi-
dence link these LTE4-mediated responses in mice to the 
P2Y12 receptor. First, treatment of the mice with a highly 
potent selective antagonist of the P2Y12 receptor, clopido-
grel, completely eliminated the histological response to LTE4 
(Fig. 4, A and B), which is associated with blockade of LTE4-
potentiated expression of IL-13, the Th2 cytokine most 
closely linked to the development of goblet cell metaplasia 
(Zhu et al., 1999), and of MUC5AC, a major mucus glyco-
protein which is controlled by IL-13 (Fig. 4 C). Second, 
LTE4  fully  amplified  pulmonary  inflammation  in  Cysltr1/
Cysltr2/ mice (Fig. 4, G–I). Lastly, the ability of LTE4 to 
potentiate mucosal inflammation and goblet cell metaplasia 
was nearly completely abrogated in the absence of P2Y12 re-
ceptors (Fig. 4, D–F). Thus, LTE4 requires P2Y12 receptors, 
but not the classical CysLTRs, to amplify the histological sig-
natures of allergen-induced pulmonary inflammation. Be-
cause LTD4 is converted in vivo to LTE4, it was somewhat 
surprising that the ligands do not behave interchangeably in 
potentiating bronchial eosinophilia in mouse or man. In ad-
dition to P2Y12-dependent effects of LTE4, LTD4 may initi-
ate inhibitory signals through CysLT2R (Jiang et al., 2007) or 
other yet-to-be-identified GPCRs that recognize LTD4 but 
not LTE4. The effects of clopidogrel in the model of airway 
disease induced by the natural allergen Der f without the use 
of exogenous LTE4 (Fig. 5) support the importance of the 
P2Y12 pathway in the integrated biology of pulmonary in-
flammation (although this does not discriminate between ef-
fects mediated by LTE4 from ADP). The blockade of the 
response by clopidogrel distinguishes the P2Y12 receptor-
dependent response of the lung to LTE4 from the clopidogrel-
resistant LTE4 response in the skin (Maekawa et al., 2008). 
Thus, it is likely that different receptors or receptor com-
plexes mediate response to the stable ligand LTE4 in distinct 
anatomical distributions.
Platelets accumulate in the lungs of individuals with asthma 
(Jeffery et al., 1989) and also are recruited to the lungs of 
OVA-sensitized and -challenged mice by an IgE-dependent 
mechanism (Pitchford et al., 2008). Activated platelets generate 
mediators (serotonin and thromboxane) that can potentiate 
airway inflammation. The essential nature of P2Y12 receptors 
for normal platelet function (Andre et al., 2003) led us to ex-
amine the effect of platelet depletion on the response of 
sensitized challenged mice to exogenous LTE4. Indeed, the 
response to LTE4 was totally abrogated by platelet depletion 
(Fig. 6, A and B). Whether the requirement for platelets is di-
rect or indirect is less clear. The fact that LTE4 did not induce 
platelet expression of CD62P (an activation marker used as a 
surrogate for ADP release; Abrams and Shattil, 1991; Fig. 6 C) 
argues that LTE4 does not trigger an ADP-dependent auto-
crine loop initiated by LTE4-mediated activation of another 
blocked the LTE4-mediated increment in MIP-1 produc-
tion (Fig. 2 B) and also reduced the response to the higher 
concentrations of LTD4, indicating that LTD4 at high con-
centrations can also activate native P2Y12 receptors, as sup-
ported by its actions as an agonist for ERK activation in the 
P2Y12 receptor transfectants (Fig. 1). MK571 suppressed MIP-1 
generation in response to both ligands (likely reflecting the 
requirement for calcium flux for chemokine generation) and 
was additive with 2-MesAMP for the suppression of the   
response to LTD4. The shRNA-mediated knockdowns of 
CysLT1R and P2Y12 receptors revealed strong dependence   
of LTD4-mediated activation on CysLT1R, whereas LTE4-
mediated responses were clearly P2Y12 receptor dependent 
(Fig. 2 C). Although there is segregation of the receptor re-
quirements for these two related ligands on the same cell, the 
ability of LTE4 to “cross over” and induce some calcium 
signaling through the CysLT1R may permit some complemen-
tarities between the CysLT1R (via Gq proteins and calcium- 
induced pathways) and P2Y12 receptors (via Gi proteins), 
particularly for chemokine generation. This is analogous to 
the cooperation by Gq-linked P2Y1 receptors with P2Y12 
receptors in regulating ADP responses of platelets (Lova et al., 
2002; Woulfe et al., 2002). The P2Y12-dependent activation 
of LAD2 cells does not likely reflect autocrine effects of re-
leased ADP because it was resistant to treatment of the cells 
with the ectonucleotidase apyrase (Fig. S2).
Surprisingly, although P2Y12 receptors were essential for 
competition between LTE4 with ADP for binding to mem-
branes of LAD2 cells (Fig. S3, A and B), they were not in-
volved in the direct low-affinity binding of [3H]LTE4 to 
these same membranes (Fig. S3 C). Additionally, LTE4 could 
not compete for binding to P2Y12 receptors expressed in iso-
lation on COS-7 cells (Fig. S3 D). The fact that P2Y12 recep-
tors do not directly bind LTE4 despite their essential nature 
implies that they are components of a complex with another 
LTE4-reactive GPCR, perhaps with the putative CysLTER 
reported in the mouse skin (Maekawa et al., 2008). The facts 
that P2Y12 receptors are required for LTE4 to activate trans-
fected CHO cells (Fig. 1) and LAD2 cells (Fig. 2), and for 
competition between LTE4 and ADP for binding to LAD2 
cells (Fig. S3 B), and that knockdown of P2Y12 receptors did 
not reduce direct binding of radiolabeled LTE4 (Fig. S3 C) 
are all consistent with this thesis. Precedents for such com-
plexes on MCs include CysLT1R and CysLT2R heterodi-
mers (Jiang et al., 2007) and a functional requirement of 
CysLT1R for the uridine diphosphate-reactive P2Y6 recep-
tor (Jiang et al., 2009). Our data indicate that presence of 
P2Y12 is required for signaling and activation by LTE4 in a 
cell-specific context.
The fact that LTE4, but not LTD4, induces bronchial eo-
sinophilia when administered by inhalation to the airways of 
individuals with asthma (Gauvreau et al., 2001) argued for 
the presence of an LTE4-reactive receptor in inflamed lung. 
In our model, which was designed to study potentiation of 
submaximal bronchial inflammation in sensitized mice, we 
found that LTE4 exceeded the potency of LTD4 for potenti-2552 LEUKOTRIENE E4 AND P2Y12 RECEPTORS | Paruchuri et al.
fetal bovine serum (Sigma-Aldrich), 2 mM l-glutamine, 0.1 mM nonessential 
amino acids, 0.2 µM 2-ME, 100 U/ml penicillin, 100 µg/ml streptomycin, 
and 2 µg/ml gentamycin supplemented with SCF, IL-6, and IL-10 (R&D 
Systems) as previously described (Ochi et al., 1999).
Calcium flux. 0.5–1 × 106 cells/sample were washed and labeled with Fura 
2-AM for 30 min at 37°C. Cells were stimulated with the indicated concen-
trations of LTD4 or LTE4, and changes in intracellular calcium concentration 
were measured using excitation at 340 and 380 nm in a fluorescence spectro-
photometer (F-4500; Hitachi; Paruchuri et al., 2008). The relative ratios of 
fluorescence emitted at 510 nm were recorded and displayed as a reflection of 
intracellular calcium concentration. In some experiments, cells were preincu-
bated with the 1 µM of the CysLT1R antagonist MK571 or with 100 µM of 
the P2Y12 receptor antagonist 2-MesAMP for 5 min before the stimulation.
Real-time quantitative PCR. The expressions of human P2Y12 receptor 
mRNA and mouse IL-13 and MUC5AC RNAs were determined with real-
time PCR performed on an ABI PRISM 7700 Sequence detection system 
(Applied Biosystems). RNA was isolated with an RNeasy mini kit (QIAGEN) 
and was treated with RNase-free DNase (Invitrogen) according to the manu-
facturer’s protocol. cDNA was synthesized from 1 µg RNA with Superscript II 
RNase H-RT (Invitrogen). RT was performed using TaqMan RT reagents. 
Primers and FAM-labeled PCR mix were purchased from SABiosciences.
shRNA knockdowns. shRNA constructs targeting human CysLT1R and 
P2Y12 receptors were purchased from Thermo Fisher Scientific. The con-
structs were cloned into a lentiviral vector (pLKo1; Thermo Fisher Scientific) 
and used to generate infectious particles with a lentiviral packaging mix 
(Virapower; Invitrogen) according to the manufacturer’s protocol. The trans-
fections were performed as described previously (Jiang et al., 2007). FACS 
analysis was used to confirm the knockdowns of CysLT1R, whereas quantita-
tive PCR was used to verify the knockdown of the P2Y12 receptor.
Generation of stable P2Y12 receptor transfectants. A human P2Y12 re-
ceptor cDNA was amplified by 30 cycles of PCR from RT total RNA extracted 
from primary hMCs. The primer sequences were 5-CAACAAGAAATG-
CAAGCCGTCGA-3 and 5-TACATTGGAGTCTCTTCATTTGG-3. 
The fragment was cloned into a TA vector (Invitrogen). After verifying the 
nucleotide sequence, the fragment was subcloned into the multiple cloning 
site of the expression vector pEF1/His B, encoding a C-terminal HIS tag. 
A plasmid expressing the P2Y12 receptor construct in the forward orienta-
tion was transfected into CHO cells using Fugene HD reagent according to 
manufacturer’s protocol. A construct in the reverse sequence was transfected 
in parallel as a negative control. Stably expressing clones were selected in 
the medium containing 1,000 µg/ml G418 (Invitrogen), and expression of 
the construct was confirmed by FACS analysis of permeabilized cells with a 
mAb against the HIS tag.
Cell activation. LAD2 cells were stimulated with the indicated concentra-
tions of LTD4 or LTE4 (Cayman Chemical) in the presence or absence of 
MK571 (Cayman Chemical) or 2-MesAMP (Sigma-Aldrich) or were pas-
sively sensitized with 2 µg/ml of human myeloma IgE (Millipore) overnight 
and stimulated with 1 µg/ml of rabbit anti–human anti-IgE (Millipore) as 
detailed elsewhere (Paruchuri et al., 2008). In some experiments, LAD2 cells 
were incubated with 10 µM apyrase (Sigma-Aldrich) to degrade extracellular 
nucleotides during the activation. The concentration of MIP-1 was mea-
sured by an ELISA (Thermo Fisher Scientific). PGD2 was quantitated by a 
PGD2-methoxylamine hydrochloride assay (Cayman Chemical).
SDS PAGE immunoblotting. After stimulation with the respective ago-
nists, 0.5 × 106 LAD2 cells and CHO cells were lysed with lysis buffer (BD) 
supplemented with protease inhibitor cocktail (Roche) and 1 mM sodium 
vanadate. Lysates were subjected to 4–12% SDS-PAGE and transferred to 
PVDF membranes. The membranes were incubated with antibodies against 
phospho and total ERK (Cell Signaling Technology) in PBS, 5% dry milk, and 
receptor. Because platelet activation involves complementary 
signaling in both Gi and Gq protein–mediated pathways (Jin 
et al., 2002; Lova et al., 2002; Woulfe et al., 2002) and P2Y12 
provides only the Gi-linked component, LTE4 (and P2Y12) 
likely synergizes in vivo with a second agonist to facilitate 
platelet functions in the lung. It is noteworthy that LTE4-
mediated potentiation of the contractile responses of both guinea 
pig and human airway smooth muscle is COX dependent 
(Christie et al., 1992a) and was attributed to secondary gener-
ation of thromboxane, a major platelet-derived eicosanoid 
(Jacques et al., 1991). In retrospect, this finding may have re-
flected  P2Y12  receptor-dependent  signaling  on  platelets  or 
other cell types. The fact that LTE4 potentiated inflammation 
only in sensitized challenged mice may reflect the previously 
described  platelet-mediated  pathway  for  leukocyte  recruit-
ment that depends on sensitization and IgE (Pitchford et al., 
2008). The complete lack of LTE4 reactivity in the face of 
platelet depletion argues against a role for MCs and other 
P2Y12-bearing cell types, at least in this model.
Our findings suggest a potential therapeutic application 
for P2Y12 receptor antagonists that may be especially relevant 
to AERD, which is associated with both high levels of 
LTE4 in the urine (Christie et al., 1992b) and selective hyper-
responsiveness to LTE4 (Christie et al., 1993). In AERD, 
both 5-LO antagonists and CysLT1R antagonists provide dis-
ease control and attenuate the consequences of aspirin chal-
lenge (Israel et al., 1993; Dahlén et al., 1998, 2002; White et al., 
2006), in which the reaction is characterized by a marked 
surge in LTE4 generation. The fact that the effects of LTE4 
persist in the absence of CysLT1R and CysLT2R implies that 
this pathway would be resistant to the available cys-LT re-
ceptor antagonists, all of which selectively block CysLT1R. 
We speculate that simultaneous interference with the bron-
choconstrictive effects of LTD4 (via CysLT1R) and with pro-
inflammatory effects of LTE4 (by P2Y12), or more complete 
blockade of 5-LO, might improve clinical efficacy. Our study 
furthermore highlights the biological significance of the struc-
tural and functional relationships between the P2Y and cys-LT–
reactive classes of GPCRs.
MATERIALS AND METHODS
Animals. All animal protocols were approved by the Dana Farber Cancer 
Institute Animal Care and Utilization Committee. BALB/c mice lacking 
both CysLT1R and CysLT2R (Cysltr1/Cysltr2/ mice) and their WT lit-
termate controls were derived as described elsewhere (Maekawa et al., 2008). 
Mice lacking P2Y12 receptors (p2ry12/ mice) were derived as described 
elsewhere (Andre et al., 2003) on a mixed C57BL/6-129 background and 
backcrossed for 10 generations with C57BL/6 mice. WT BALB/c and C57BL/6 
mice were purchased from Taconic.
Cell culture. The LAD2 line (Kirshenbaum et al., 2003) isolated from the 
bone marrow of a patient with MC leukemia was a gift from A. Kirshenbaum 
(National Institutes of Health). These cells were cultured in StemPro-34 
(Invitrogen) supplemented with 2 mM l-glutamine (Invitrogen), 100 IU/ml 
Pen-strep (Invitrogen), and 100 ng/ml stem cell factor (SCF; Thermo Fisher 
Scientific). Cell culture medium was hemidepleted every week with fresh 
medium and 100 ng/ml SCF. CHO cells were grown in DMEM/F-12 with 
10% FBS and 100 IU/ml Pen-strep (Invitrogen). Primary cord blood MCs 
were derived in vitro in RPMI 1640 (Invitrogen) supplemented with 10% JEM VOL. 206, October 26, 2009 
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dependent bronchovascular bundles from the lung sections obtained for each 
animal in the different experimental groups. The length of basal lamina of 
corresponding bronchus was measured by ImageJ image analysis software 
(National Institutes of Health). Only the comparable large-caliber pretermi-
nal bronchi (diameter 200–220 µm) were examined because minimal changes 
occur in terminal bronchioles. The data were expressed as the mean of gob-
let cell counts stained in each bronchus in each section per millimeter of 
bronchial basal lamina.
Statistics. Data are expressed as mean ± SEM from at least three experi-
ments except where otherwise indicated. Significance was determined with 
the Welch’s test for samples of unequal variance. Analysis of variance was 
used to test differences between multiple groups.
Online supplemental material. Fig. S1 shows the dose-dependent effects 
of LTE4 and LTD4 on ERK activation in CHO cells stably transfected with 
the human P2Y12 construct. Fig. S2 shows the effect of apyrase treatment on 
LT-mediated activation of LAD2 cells. Fig. S3 shows competitive ligand 
binding assays. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20091240/DC1.
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0.1% Tween-20 (1:1,000) overnight at 4°C on shaker and then with second-
ary antibody (peroxidase-conjugated anti–rabbit or anti–mouse). Bands were 
visualized with enhanced chemiluminescence (Thermo Fisher Scientific).
Binding assays. [3H] LTD4 ([14,15,19,20-3H(N)]; specific activity 100–240 
Ci/mmol; PerkinElmer) was converted to [3H]LTE4 by the dipeptidases 
present in the serum. In brief, 100 µl (80 nM) [3H]LTD4 was incubated with 
100 µl of 10% serum for 2 h at room temperature. The converted product 
was extracted into 400 µl of methanol, evaporated in the presence of nitro-
gen, and diluted to the required concentration with the binding buffer for 
the binding assay. The conversion was confirmed by running an aliquot on 
high-performance reverse-phase liquid chromatography. The fraction elut-
ing with the LTE4 peak accounted for >99% of the radioactivity used in the 
assays. The specific activity of the resultant LTE4 was consistently 80–100% 
that of the LTD4 from which it was converted. [3H]ADP and [3H]LTE4 
binding assays were performed using membrane proteins as described earlier 
(Maekawa et al., 2001). In brief, cells were washed in PBS, resuspended in 
PBS supplemented with protease inhibitor cocktail, and lysed by sonication 
for 5 min. The lysed cells were centrifuged at 100,000 g for 45 min and the 
microsomal pellet was resuspended in 1 ml PBS. Protein concentration was 
determined using a Protein Assay kit (Bio-Rad Laboratories). 50 µg of mem-
brane protein was incubated for 1 h at room temperature in 250 µl of 10 mM 
Hepes/KOH, pH 7.4, with various concentrations of radiolabeled ligand 
and cold competitor. Bound [3H] was separated from free [3H] by filtration 
through GF/C filters (GE Healthcare) and washed twice with 10 mM 
Hepes/KOH, pH 7.4, containing 0.01% BSA. The residual membrane-
associated [3H] on the filter was determined in 2 ml scintillation fluid by  
counter (PerkinElmer). For [3H]ADP, specific binding was determined by 
subtracting the amount of [3H] bound in the presence of 100 µM 2-MesADP 
from total binding. For [3H]LTE4, nonspecific binding was calculated as the 
residual radioactivity bound in the presence of 10 µM of unlabeled LTE4.
Induction of pulmonary inflammation. Male BALB/c mice (6–8 wk 
old) received i.p. injections of 10 µg of reagent-grade chicken egg OVA pre-
cipitated with 2.25 µg aluminum hydroxide on days 0 and 7. On days 14–16, 
the mice received single intranasal doses of 2.2 nmol LTD4, LTE4, or buffer. 
30 min after each dose, the mice were exposed to an aerosol of 0.1% OVA 
for 30 min delivered by an ultrasonic nebulizer. As a positive control group, 
some mice received 1% OVA without LTD4 or LTE4 pretreatment. The 
mice were euthanized 24 h after their third and final OVA aerosol challenge. 
In some experiments, the mice received 500 µg/ml clopidogrel in drinking 
water for 3 d before the first intranasal dose of LTs. The treatment was con-
tinued throughout the procedure. For Der f–mediated pulmonary inflamma-
tion, 6–8-wk-old C57BL/6 mice were lightly anaesthetized and received 
either 3 or 10 µg Der f extract (Greer Laboratories) on days 0, 3, 7, 10, 14, 
and 17. Some mice received clopidogrel throughout the duration of the ex-
periment. Mice were euthanized 24 h after the last intranasal instillation.
Platelet depletion. Sensitized mice were treated i.v. with 50 µg (2 µg/g 
body  weight)  of  a  monoclonal  rat  IgG  directed  against  mouse  CD42b 
(GPIb) or an equal amount of isotype control (both from Emfret Analytics; 
Nieswandt et al., 2000). Each antibody was diluted in 50 µl of sterile saline. 
The depletion of platelets was confirmed by automated counting.
Histological assessment . The left lungs were fixed for at least 8 h in 4% 
paraformaldehyde and embedded in glycol methacrylate, as described previ-
ously (Kim et al., 2006). Then, 2.5-µm-thick glycol methacrylate sections 
were stained with H&E for general morphological examination. For histo-
logical study of the mucus-secreting cells of the epithelium (goblet cells) of 
the airways, lung sections were stained with PAS. The extent of cellular in-
filtration in the bronchovascular bundles was evaluated without knowledge 
of the particular treatment and was categorized arbitrarily into the following 
grades: 0, no inflammation; 1, mild inflammation; 2, moderate inflamma-
tion; and 3, severe inflammation. 15 bronchovascular bundles of each mouse 
were evaluated. The stained goblet cells were enumerated in at least four in-2554 LEUKOTRIENE E4 AND P2Y12 RECEPTORS | Paruchuri et al.
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